Published 5 days ago • loading... • Updated 4 days ago

Emerging Insights From MARIPOSA: OS Updates From Amivantamab/Lazertinib in Advanced NSCLC

Summary by cancernetwork.com

Panelists discuss how the MARIPOSA study demonstrated significant progression-free survival and overall survival (OS) benefits with amivantamab plus lazertinib vs osimertinib monotherapy, with mature overall survival data showing a 25% improvement in survival outcomes.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

oncnursingnews.com

Reposted by

cancernetwork.com

Emerging Insights From MARIPOSA: OS Updates From Amivantamab/Lazertinib in Advanced NSCLC

Panelists discuss how the MARIPOSA study findings demonstrated significant progression-free survival and overall survival benefits with amivantamab plus lazertinib vs osimertinib monotherapy, with mature overall survival data showing a 25% improvement in survival outcomes.

5 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right